CG Invites Co

CG Invites Co Enterprise Value

The Enterprise Value (EV) of CG Invites Co (083790.KQ) as of Nov 1, 2026 is 117.65 B KRW. In the previous year, Enterprise Value (EV) was 113.50 B KRW — a change of 3.65% (higher).

Enterprise Value

117.65 BKRW

YoY

3.65%

Last updated:

Enterprise Value (EV) of CG Invites Co is 2025 117.65 B KRW. Enterprise Value (EV) of CG Invites Co was 2024 113.50 B KRW. It decreases by 3.65% higher compared to the previous year.

The CG Invites Co Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
-8.66 B KRW
Jan 1, 2019
23.49 B KRW
Jan 1, 2020
30.93 B KRW
Jan 1, 2021
57.59 B KRW
Jan 1, 2022
100.38 B KRW
Jan 1, 2023
147.39 B KRW
Jan 1, 2024
113.50 B KRW
Jan 1, 2025
117.65 B KRW
The CG Invites Co Enterprise Value history
YEAREnterprise ValueYoY
117.65 BKRW+3.65%
113.50 BKRW-22.99%
147.39 BKRW+46.82%
100.38 BKRW+74.30%
57.59 BKRW+86.18%
30.93 BKRW+31.68%
23.49 BKRW-371.30%
-8.66 BKRW-108.66%
100.00 BKRW-7.07%
107.61 BKRW-13.94%
125.05 BKRW-24.29%
165.17 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CG Invites Co Stock analysis

What does CG Invites Co do? CrystalGenomics, Inc. generates revenue through its Finished Pharmaceuticals Manufacturing segment, which produces and sells finished pharmaceuticals. The Pharmaceutical R&D Division provides clinical trial analysis and technical services while also selling new drugs. The company also operates in the real estate leasing business under the segment structure. The Others segment manufactures and sells hot fats and other household items. Revenue streams are derived from pharmaceutical manufacturing, R&D services, real estate leasing, and household product sales. The primary buyers for finished pharmaceuticals include healthcare providers and distributors. Clinical trial analysis and new drug sales target pharmaceutical companies and research institutions. Real estate leasing serves commercial tenants, while hot fats and household items are sold to retail consumers. The company's segments collectively serve diverse markets across healthcare, real estate, and consumer goods. CrystalGenomics, Inc. focuses on therapeutic discovery and development, with its R&D Division driving innovation in new drug sales. The Finished Pharmaceuticals Manufacturing segment ensures steady supply of established products. Real estate leasing and household item sales provide additional revenue streams. The company's business model integrates pharmaceutical production, research, and non-pharmaceutical ventures. CG Invites Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CG Invites Co stock

Enterprise Value (EV) of CG Invites Co is 117.65 B KRW in 2025.

Enterprise Value (EV) of CG Invites Co changed from 113.50 B KRW to 117.65 B KRW, representing a 3.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) CG Invites Co since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s KRW, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' KRW varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s CG Invites Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — CG Invites Co

All Key Metrics — CG Invites Co